Skip to main content

Table 3 Treatment approach for subsequent therapy in patients after the progression of disease with therapy failure

From: Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma

Disease progression with no previous exposure to anti-angiogenic therapy VEGFR Inhibitors- Axitinib, Cabozantinib, Sunitinib, Pazopanib, Lenvatinib plus everolimus
Nivolumab plus Ipilimumab if no previous exposure Ipilimumab
Disease progression with VEGFR inhibitor plus immunotherapy Cabozantinib, Lenvatinib plus everolimus
Disease progression with VEGFR inhibitor without prior exposure to immune checkpoint inhibitors Nivolumab